184 related articles for article (PubMed ID: 29501322)
1. Do sulphonylureas still have a place in clinical practice?
Khunti K; Chatterjee S; Gerstein HC; Zoungas S; Davies MJ
Lancet Diabetes Endocrinol; 2018 Oct; 6(10):821-832. PubMed ID: 29501322
[TBL] [Abstract][Full Text] [Related]
2. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
Scheen AJ
Diabetes Metab; 2018 Nov; 44(5):386-392. PubMed ID: 30126735
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
Rosenstock J; Marx N; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Bluhmki E; Patel S; Johansen OE; Woerle HJ
Diab Vasc Dis Res; 2013 Jul; 10(4):289-301. PubMed ID: 23449634
[TBL] [Abstract][Full Text] [Related]
6. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.
Abdelmoneim AS; Eurich DT; Light PE; Senior PA; Seubert JM; Makowsky MJ; Simpson SH
Diabetes Obes Metab; 2015 Jun; 17(6):523-532. PubMed ID: 25711240
[TBL] [Abstract][Full Text] [Related]
8. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Gooßen K; Gräber S
Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
[TBL] [Abstract][Full Text] [Related]
9. Comparative tolerability of sulphonylureas in diabetes mellitus.
Harrower AD
Drug Saf; 2000 Apr; 22(4):313-20. PubMed ID: 10789825
[TBL] [Abstract][Full Text] [Related]
10. The right place for Sulphonylureas today.
Webb DR; Davies MJ; Jarvis J; Seidu S; Khunti K
Diabetes Res Clin Pract; 2019 Nov; 157():107836. PubMed ID: 31479704
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes.
Monami M; Dicembrini I; Kundisova L; Zannoni S; Nreu B; Mannucci E
Diabetes Obes Metab; 2014 Sep; 16(9):833-40. PubMed ID: 24635837
[TBL] [Abstract][Full Text] [Related]
12. Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?
John M; Kalra S; Nair T
Indian Heart J; 2020; 72(4):312-315. PubMed ID: 32861392
[TBL] [Abstract][Full Text] [Related]
13. Mortality risk with sulphonylureas compared to metformin.
Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):885-90. PubMed ID: 24533964
[TBL] [Abstract][Full Text] [Related]
14. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
[TBL] [Abstract][Full Text] [Related]
15. Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study.
Douros A; Dell'Aniello S; Yu OHY; Suissa S
Diabetes Obes Metab; 2020 Feb; 22(2):254-262. PubMed ID: 31596043
[TBL] [Abstract][Full Text] [Related]
16. [Increased cardiovascular risk in patients with type 2 diabetes treated with sulfonylurea?].
Asvold BO; Jonsbu M; Grill V
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2560-4. PubMed ID: 11070997
[TBL] [Abstract][Full Text] [Related]
17. The role of sulphonylureas in the management of type 2 diabetes mellitus.
Rendell M
Drugs; 2004; 64(12):1339-58. PubMed ID: 15200348
[TBL] [Abstract][Full Text] [Related]
18. [Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA® trial].
Gallwitz B; Thiemann S; Wörle HJ; Marx N
Dtsch Med Wochenschr; 2015 May; 140(11):831-4. PubMed ID: 26080724
[TBL] [Abstract][Full Text] [Related]
19. The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes.
Kar P; Holt RI
Cardiovasc Drugs Ther; 2008 Jun; 22(3):207-13. PubMed ID: 18288596
[TBL] [Abstract][Full Text] [Related]
20. Clinical profile of glimepiride.
Draeger E
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S139-46. PubMed ID: 8529506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
